- Email: [email protected]
1991)
European Neuropsychopharmacoiogy, c~ 1991 Elsevier Science Publishers
571
1 (1991) 511-573 B.V. / All rights reserved / 0924-977X/91/$3.50
Author
index to volume
Authors of the abstracts of the IVth Cowress of the European the following index (see separate index-on pp: 481-485/.
1 (1990/1991)
College of Neuropsychopharmacology,
Abate, G., see Senin, U., 511 Ailing, C., see Simonsson, P., 503 Altamura, A.C., Regazzetti, M.G. and Porta, M., Nimodipine in human alcohol withdrawal syndrome ~ an open study, 37 Anderer, P., see Saletu, B., 27 Ansseau, M., Von Frenckell, R., Gerard, M.-A., Mertens, C., De Wilde, J., Botte, L., Devoitille, J.-M., Evrard, J.-L., De Nayer, A., Darimont, P., Mirel, J., Troisfontaines, B., Toussaint, C., Couzinier, J.-P., Demarez, J.-P. and Serre, C., Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, 113 Appelberg, B., see Lahdelma, R.-L., 535 Banquet, J.-P., see Gunther, W., 143 Bartels, M., see Becker, T., 83 Becker, T., Elmer, K., Mechela, B., Schneider, F., Taubert, S., Schroth, G., Grodd, W., Bartels, M. and Beckmann, H., MRI findings in medial temporal lobe structures in schizophrenia, 83 Beckmann, H., see Becker, T., 83 Blennow, K., Wallin, A., Fredman, P., Gottfries, C.-G., Karlsson, 1. and Svennerholm, L., Intrathecal synthesis of immunoglobulins in patients with Alzheimer’s disease, 79 Botte, L., see Ansseau, M., 113 Bourin, M., see Koszycki, D., 137 Bradwejn, J., see Koszycki, D., 137 Bscheid, I., see Gunther, W., 143 Bucci, P., see Galderisi, S., 51 Butcher, S.P., Davis, S. and Morris, R.G.M., A dose-related impairment of spatial learning by the NMDA receptor antagonist, 2-amino-5-phosphonovalerate (AP5), 15 Carlsson, A., see Wallin, A., 165 Cloez, I., see Harel-Dupas, C., 157 Conti, L., see Marazziti, D., 169 Cooper, S.J., Kelly, C.B., McGilloway, S. and Gilliland, A., p2Adrenoceptor antagonism in anxiety, 75 Couzinier, J.-P., see Ansseau, M., 113 Cutrufo, C., see Volterra, G., 519 Dagerlind, A., see Schalling, M., 17 Dahl, S.G., see Heimstad, E., 127 Darimont, P., see Ansseau, M., 113 Davies, C., see Hughes, M.J., 45 Davis, S., see Butcher, S.P., 15 De Nayer, A., see Ansseau, M., 113 De Wilde, J., see Ansseau, M., 113 Delcker, A. and Gaertner, H.J., Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor - an open study, 177
volume 1, no. 3. are not included in
Demarez, J.-P., see Ansseau, M., 113 Devoitille, J.-M., see Ansseau, M., 113 Di Gregorio, M.R., see Galderisi, S., 51 Edvardsen, O., see Heimstad, E., 127 Ekman, R., see Wallin, A., 165 Elmer, K., see Becker, T., 83 Engel, J.A., see Soderpalm, B., 7 Evrard, J.-L., see Ansseau, M., I1 3 Fava, G.A., see Sonino, N., 63 Ferrin, T.E., see Heimstad, E., 127 Fieschi, C., see Senin, U., 511 Fillion, G., see Harel-Dupas, C., 157 Fredman, P., see Blennow, K., 79 Fritze, J., Sofic, E., Pftiller, H., Lanczik, M. and Riederer, P., Adrenergic-cholinergic imbalances: the physostigmine-syndrome is not antagonized by the MAO-A inhibitor brofaromine, 2 1 Gaertner, H.J., see Delcker, A., 177 Galderisi, S., Mucci, A., Di Gregorio, M.R., Bucci, P., Maj, M. and Kemali, D., C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment, 51 Georgi, P., see Sauer, H., 71 Gerard, M.-A., see Ansseau, M., 113 Gerlach, J., see Lublin, H., 541 Gilliland, A., see Cooper, S.J., 75 Gori, G., see Senin, U., 51 I Gottfries, C-G., see Blennow, K., 79 Gottfries, C.-G., see Wallin, A., 165 Gottfries, C.G, Pharmacological treatment strategies in Alzheimer type dementia, I Grodd, W., see Becker, T., 83 Grtinberger, J., see Saletu. B., 27 Guala, A., see Senin, U., 511 Gunther, W., Steinberg, R., Streck, P., Banquet, J.-P., Bscheid, I., Raith, L., Riedel, R.. Klages, U. and Stiltz, I., Brain dysfunction on psychiatric patients during music perception measured by EEG mapping: relation to motor dysfunction and influence of neuroieptic drugs, 143 Haefely, W., Psychopharmacology of anxiety, 89 Hagert, U., see Lubhn, H., 541 Harel-Dupas, C., Cloez, I. and Fillion, G., Antagonism by antidepressant drugs of the inhibitory effect of trifluoromethylphenylpiperazine (TFMPP) on [sH]acetylcholine release in rat or guinea-pig hippocampal synaptosomes, 157 Harima, A., Shimizu, H. and Takagi, H., Analgesic effect of Larginine in patients with persistent pain. 529
572 Heimstad, E., Edvardsen, 10., Ferrin, T.E. and Dahl, S.G., Molecular structure and dynamics of tricyclic antidepressant drugs, 127 Henningsen, H., see Sauer, H., 71 H6kfelt, T., see Schalling, M., 17 Hughes, M.J., Davies, C., Sykes, E.A. and Steinberg, H., Mapping and interpreting complex interactions between psychoactive drugs by simple computer-generated models, 45 lnagawa, K. and Watanabe, S., Effects of diazepam and chlorpromazine on socially induced anxiety in pigeons, 549 Karlsson, I., see Blennow, K., 79 Karlsson, I., see Wallin, A., 165 Kasper, S., Kick, H., Voll, G. and Vieira, A., Therapeutic sleep deprivation and antidepressant medication in patients with major depression, 107 Katila, H., see Lahdelma, R.-L., 535 Kelly, C.B., see Cooper, S.J., 75 Kemali, D., see Galderisi, S., 51 Kempennan, C.J.F. and Van den Hoofdakker, R.H., Neuroleptic malignant syndrome (NMS): challenge with zuclopenthixol and follow-up a case report, 67 Kick, H., see Kasper, S., I07 Klages, U., see Gfinther, W., 143 Klieser, E., see Strauss, W.H., 101 Koszycki, D., Bradwejn, J. and Bourin, M., Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in healthy volunteers, 137 Kuoppasalmi, K., see Lahdelma, R.-L., 535 Kfifferle, B., see Saletu, B., 27 Lahdelma, R.-L., Appelberg, B., Kuoppasalmi, K., Katila, H. and Rim6n, R., Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients, 535 Lanczik, M., see Fritze, J., 21 Lecci, A., see Volterra, G., 519 Lindquist, C., see Schalling, M., 17 Lublin, H., Gerlach, J., Hagert, U., Meidahl, B., Molbjerg, C., Pedersen, V., Rendtorff, C. and Tolvanen, E., Zuclopenthixol, a combined dopamine DI/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia, 541 Maj, M., see Galderisi, S., 51 Marazziti, D. and Conti, L., Aggression and suicide attempts: preliminary data, 169 Marini, G., see Senin, U., 511 McGilloway, S., see Cooper, S.J., 75 Mechela, B., see Becker, T., 83 Meidahl, B., see Lublin, H., 541 Mertens, C., see Ansseau, M., 113 Miczek, K.A., see Olivier, B., 97 Mirel, J., see Ansseau, M., 113 Molbjerg, C., see Lublin, H., 541 Moller, S.E., 5-HT uptake inhibitors and tricyclic antidepressants: relation between tryptophan availability and clinical response in depressed patients, 41 Morphy, M.A., see Sonino, N., 63 Morris, R.G.M., see Butcher, S.P., 15 Mos, J., see Olivier, B., 97 Mucci, A., see Galderisi, S., 51
O'Hanlon, J.F., Review of buspirone's effects on human performance and related variables, 489 Ohman, R., see Simonsson, P., 503 Olivier, B., Mos, J. and Miczek, K.A., Ethopharmacological studies of anxiolytics and aggression, 97 Oreland, L., see Simonsson, P., 503 Parnetti, L., see Senin, U., 511 Pedersen, R.C., see Sonino, N., 63 Pedersen, V., see Lublin, H., 541 Pftiller, H., see Fritze, J., 21 Popik, P. and Van Ree, J.M., Oxytocin but not vasopressin facilitates social recognition following injection into the medial preoptic area of the rat brain, 555 Porta, M., see Altamura, A.C., 37 Raith, L., see Gtinther, W., 143 Ramsey, N.F. and Van Ree, J.M., Chronic pretreatment with naltrexone facilitates acquisition of intravenous cocaine self-administration in rats, 55 Regazzetti, M.G., see Altamura, A.C., 37 Regn611, G., see Simonsson, P., 503 Rendtorff, C., see Lublin, H., 541 Riedel, R., see Giinther, W., 143 Riederer, P., see Fritze, J., 21 Rimdn, R., see Lahdelma, R.-L., 535 Saletu, B., Kfifferle, B., Anderer, P., Grtinberger, J. and Steinberger, K., EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol, 27 Sauer, H., Schr6der, J., Henningsen, H., Wilhelm, K.-R. and Georgi, P., Regional cerebral blood flow in endogenous psychoses, measured by 99mycHMPAO-SPECT, 71 Schalling, M., Dagerlind, A., Stieg, P.. Lindquist, C. and H6kfelt, T., Colocalization of neurotransmitters analyzed by in situ hybridization, 17 Schneider, F., see Becker, T., 83 Schroth, G., see Becker, Y., 83 Schr6der, J., see Sauer, H., 71 Sekiguchi, R., Wolterink, G. and Van Ree, J.M.. Analysis of the influence of vasopressin neuropeptides on social recognition of rats, 123 Senin, U., Abate, G., Fieschi, C., Gori, G., Guala, A., Marini, G., Villardita, C. and Parnetti, L., Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study, 511 Serre, C., see Ansseau, M., 113 Shimizu, H., see Harima, A., 529 Simonsson, P., Tr/iskman-Bendz, L., Ailing, C., Oreland, L., Regn611, G. and CIhman, R., Peripheral serotonergic markers in patients with suicidal behavior, 503 S6derpalm, B. and Engel, J.A., Serotonergic involvement in conflict behaviour, 7 Sofic, E., see Fritze, J., 21 Sonino, N., Fava, G.A., Morphy, M.A. and Pedersen, R.C., Effects of metyrapone and dexamethasone on pro-gammaMSH and ACTH levels in depressed patients, 63 Steinberg, H., see Hughes, M.J., 45 Steinberg, R., see Gfinther, W., 143 Steinberger, K., see Saletu, B., 27 Stieg, P., see Schalling, M., 17 Stiltz, I., see Gfinther, W., 143
573 Strauss, W.H. and Klieser, E., Psychotropic effects of ritanserin, a selective $2 antagonist: an open study, 101 Streck, P., see G(inther, W., 143 Svennerholm, L., see Blennow, K., 79 Svennerholm, L., see Wallin, A., 165 Sykes, E.A., see Hughes, M.J., 45 Takagi, H., see Harima, A., 529 Taubert, S., see Becker, T., 83 Tolvanen, E., see Lublin, H., 541 Toussaint, C., see Ansseau, M., 113 Tr/iskman-Bendz, L., see Simonsson, P., 503 Troisfontaines, B., see Ansseau, M., 113 Van Van Van Van
den Hoofdakker, R.H., see Kemperman, C.J.F., 67 Ree, J.M., see Popik, P., 555 Ree, J.M., see Ramsey, N.F., 55 Ree, J.M., see Sekiguchi, R., 123
Vieira, A., see Kasper, S., 107 Villardita, C., see Senin, U., 511 Voll, G., see Kasper, S., 107 Volterra, G., Cutrufo, C. and Lecci, A., m-Trifluoromethylphenylpiperazine and m-chlorophenylpiperazine-induced hypothermia in mice is reversed by tricyclic antidepressants and other drugs, 519 Von Frenckell, R., see Ansseau, M., 113 Wallin, A., Carlsson, A., Ekman, R., Gottfries, C.-G., Karlsson, I., Svennerholm, L. and Widerl6v, E., Hypothalamic monoamines and neuropeptides in dementia, 165 Wallin, A., see Blennow, K., 79 Watanabe, S., see Inagawa, K., 549 Widerl6v, E., see Wallin, A., 165 Wilhelm, K.-R., see Sauer, H., 71 Wolterink, G., see Sekiguchi, R., 123
571
1 (1991) 511-573 B.V. / All rights reserved / 0924-977X/91/$3.50
Author
index to volume
Authors of the abstracts of the IVth Cowress of the European the following index (see separate index-on pp: 481-485/.
1 (1990/1991)
College of Neuropsychopharmacology,
Abate, G., see Senin, U., 511 Ailing, C., see Simonsson, P., 503 Altamura, A.C., Regazzetti, M.G. and Porta, M., Nimodipine in human alcohol withdrawal syndrome ~ an open study, 37 Anderer, P., see Saletu, B., 27 Ansseau, M., Von Frenckell, R., Gerard, M.-A., Mertens, C., De Wilde, J., Botte, L., Devoitille, J.-M., Evrard, J.-L., De Nayer, A., Darimont, P., Mirel, J., Troisfontaines, B., Toussaint, C., Couzinier, J.-P., Demarez, J.-P. and Serre, C., Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, 113 Appelberg, B., see Lahdelma, R.-L., 535 Banquet, J.-P., see Gunther, W., 143 Bartels, M., see Becker, T., 83 Becker, T., Elmer, K., Mechela, B., Schneider, F., Taubert, S., Schroth, G., Grodd, W., Bartels, M. and Beckmann, H., MRI findings in medial temporal lobe structures in schizophrenia, 83 Beckmann, H., see Becker, T., 83 Blennow, K., Wallin, A., Fredman, P., Gottfries, C.-G., Karlsson, 1. and Svennerholm, L., Intrathecal synthesis of immunoglobulins in patients with Alzheimer’s disease, 79 Botte, L., see Ansseau, M., 113 Bourin, M., see Koszycki, D., 137 Bradwejn, J., see Koszycki, D., 137 Bscheid, I., see Gunther, W., 143 Bucci, P., see Galderisi, S., 51 Butcher, S.P., Davis, S. and Morris, R.G.M., A dose-related impairment of spatial learning by the NMDA receptor antagonist, 2-amino-5-phosphonovalerate (AP5), 15 Carlsson, A., see Wallin, A., 165 Cloez, I., see Harel-Dupas, C., 157 Conti, L., see Marazziti, D., 169 Cooper, S.J., Kelly, C.B., McGilloway, S. and Gilliland, A., p2Adrenoceptor antagonism in anxiety, 75 Couzinier, J.-P., see Ansseau, M., 113 Cutrufo, C., see Volterra, G., 519 Dagerlind, A., see Schalling, M., 17 Dahl, S.G., see Heimstad, E., 127 Darimont, P., see Ansseau, M., 113 Davies, C., see Hughes, M.J., 45 Davis, S., see Butcher, S.P., 15 De Nayer, A., see Ansseau, M., 113 De Wilde, J., see Ansseau, M., 113 Delcker, A. and Gaertner, H.J., Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor - an open study, 177
volume 1, no. 3. are not included in
Demarez, J.-P., see Ansseau, M., 113 Devoitille, J.-M., see Ansseau, M., 113 Di Gregorio, M.R., see Galderisi, S., 51 Edvardsen, O., see Heimstad, E., 127 Ekman, R., see Wallin, A., 165 Elmer, K., see Becker, T., 83 Engel, J.A., see Soderpalm, B., 7 Evrard, J.-L., see Ansseau, M., I1 3 Fava, G.A., see Sonino, N., 63 Ferrin, T.E., see Heimstad, E., 127 Fieschi, C., see Senin, U., 511 Fillion, G., see Harel-Dupas, C., 157 Fredman, P., see Blennow, K., 79 Fritze, J., Sofic, E., Pftiller, H., Lanczik, M. and Riederer, P., Adrenergic-cholinergic imbalances: the physostigmine-syndrome is not antagonized by the MAO-A inhibitor brofaromine, 2 1 Gaertner, H.J., see Delcker, A., 177 Galderisi, S., Mucci, A., Di Gregorio, M.R., Bucci, P., Maj, M. and Kemali, D., C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment, 51 Georgi, P., see Sauer, H., 71 Gerard, M.-A., see Ansseau, M., 113 Gerlach, J., see Lublin, H., 541 Gilliland, A., see Cooper, S.J., 75 Gori, G., see Senin, U., 51 I Gottfries, C-G., see Blennow, K., 79 Gottfries, C.-G., see Wallin, A., 165 Gottfries, C.G, Pharmacological treatment strategies in Alzheimer type dementia, I Grodd, W., see Becker, T., 83 Grtinberger, J., see Saletu. B., 27 Guala, A., see Senin, U., 511 Gunther, W., Steinberg, R., Streck, P., Banquet, J.-P., Bscheid, I., Raith, L., Riedel, R.. Klages, U. and Stiltz, I., Brain dysfunction on psychiatric patients during music perception measured by EEG mapping: relation to motor dysfunction and influence of neuroieptic drugs, 143 Haefely, W., Psychopharmacology of anxiety, 89 Hagert, U., see Lubhn, H., 541 Harel-Dupas, C., Cloez, I. and Fillion, G., Antagonism by antidepressant drugs of the inhibitory effect of trifluoromethylphenylpiperazine (TFMPP) on [sH]acetylcholine release in rat or guinea-pig hippocampal synaptosomes, 157 Harima, A., Shimizu, H. and Takagi, H., Analgesic effect of Larginine in patients with persistent pain. 529
572 Heimstad, E., Edvardsen, 10., Ferrin, T.E. and Dahl, S.G., Molecular structure and dynamics of tricyclic antidepressant drugs, 127 Henningsen, H., see Sauer, H., 71 H6kfelt, T., see Schalling, M., 17 Hughes, M.J., Davies, C., Sykes, E.A. and Steinberg, H., Mapping and interpreting complex interactions between psychoactive drugs by simple computer-generated models, 45 lnagawa, K. and Watanabe, S., Effects of diazepam and chlorpromazine on socially induced anxiety in pigeons, 549 Karlsson, I., see Blennow, K., 79 Karlsson, I., see Wallin, A., 165 Kasper, S., Kick, H., Voll, G. and Vieira, A., Therapeutic sleep deprivation and antidepressant medication in patients with major depression, 107 Katila, H., see Lahdelma, R.-L., 535 Kelly, C.B., see Cooper, S.J., 75 Kemali, D., see Galderisi, S., 51 Kempennan, C.J.F. and Van den Hoofdakker, R.H., Neuroleptic malignant syndrome (NMS): challenge with zuclopenthixol and follow-up a case report, 67 Kick, H., see Kasper, S., I07 Klages, U., see Gfinther, W., 143 Klieser, E., see Strauss, W.H., 101 Koszycki, D., Bradwejn, J. and Bourin, M., Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in healthy volunteers, 137 Kuoppasalmi, K., see Lahdelma, R.-L., 535 Kfifferle, B., see Saletu, B., 27 Lahdelma, R.-L., Appelberg, B., Kuoppasalmi, K., Katila, H. and Rim6n, R., Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients, 535 Lanczik, M., see Fritze, J., 21 Lecci, A., see Volterra, G., 519 Lindquist, C., see Schalling, M., 17 Lublin, H., Gerlach, J., Hagert, U., Meidahl, B., Molbjerg, C., Pedersen, V., Rendtorff, C. and Tolvanen, E., Zuclopenthixol, a combined dopamine DI/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia, 541 Maj, M., see Galderisi, S., 51 Marazziti, D. and Conti, L., Aggression and suicide attempts: preliminary data, 169 Marini, G., see Senin, U., 511 McGilloway, S., see Cooper, S.J., 75 Mechela, B., see Becker, T., 83 Meidahl, B., see Lublin, H., 541 Mertens, C., see Ansseau, M., 113 Miczek, K.A., see Olivier, B., 97 Mirel, J., see Ansseau, M., 113 Molbjerg, C., see Lublin, H., 541 Moller, S.E., 5-HT uptake inhibitors and tricyclic antidepressants: relation between tryptophan availability and clinical response in depressed patients, 41 Morphy, M.A., see Sonino, N., 63 Morris, R.G.M., see Butcher, S.P., 15 Mos, J., see Olivier, B., 97 Mucci, A., see Galderisi, S., 51
O'Hanlon, J.F., Review of buspirone's effects on human performance and related variables, 489 Ohman, R., see Simonsson, P., 503 Olivier, B., Mos, J. and Miczek, K.A., Ethopharmacological studies of anxiolytics and aggression, 97 Oreland, L., see Simonsson, P., 503 Parnetti, L., see Senin, U., 511 Pedersen, R.C., see Sonino, N., 63 Pedersen, V., see Lublin, H., 541 Pftiller, H., see Fritze, J., 21 Popik, P. and Van Ree, J.M., Oxytocin but not vasopressin facilitates social recognition following injection into the medial preoptic area of the rat brain, 555 Porta, M., see Altamura, A.C., 37 Raith, L., see Gtinther, W., 143 Ramsey, N.F. and Van Ree, J.M., Chronic pretreatment with naltrexone facilitates acquisition of intravenous cocaine self-administration in rats, 55 Regazzetti, M.G., see Altamura, A.C., 37 Regn611, G., see Simonsson, P., 503 Rendtorff, C., see Lublin, H., 541 Riedel, R., see Giinther, W., 143 Riederer, P., see Fritze, J., 21 Rimdn, R., see Lahdelma, R.-L., 535 Saletu, B., Kfifferle, B., Anderer, P., Grtinberger, J. and Steinberger, K., EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol, 27 Sauer, H., Schr6der, J., Henningsen, H., Wilhelm, K.-R. and Georgi, P., Regional cerebral blood flow in endogenous psychoses, measured by 99mycHMPAO-SPECT, 71 Schalling, M., Dagerlind, A., Stieg, P.. Lindquist, C. and H6kfelt, T., Colocalization of neurotransmitters analyzed by in situ hybridization, 17 Schneider, F., see Becker, T., 83 Schroth, G., see Becker, Y., 83 Schr6der, J., see Sauer, H., 71 Sekiguchi, R., Wolterink, G. and Van Ree, J.M.. Analysis of the influence of vasopressin neuropeptides on social recognition of rats, 123 Senin, U., Abate, G., Fieschi, C., Gori, G., Guala, A., Marini, G., Villardita, C. and Parnetti, L., Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study, 511 Serre, C., see Ansseau, M., 113 Shimizu, H., see Harima, A., 529 Simonsson, P., Tr/iskman-Bendz, L., Ailing, C., Oreland, L., Regn611, G. and CIhman, R., Peripheral serotonergic markers in patients with suicidal behavior, 503 S6derpalm, B. and Engel, J.A., Serotonergic involvement in conflict behaviour, 7 Sofic, E., see Fritze, J., 21 Sonino, N., Fava, G.A., Morphy, M.A. and Pedersen, R.C., Effects of metyrapone and dexamethasone on pro-gammaMSH and ACTH levels in depressed patients, 63 Steinberg, H., see Hughes, M.J., 45 Steinberg, R., see Gfinther, W., 143 Steinberger, K., see Saletu, B., 27 Stieg, P., see Schalling, M., 17 Stiltz, I., see Gfinther, W., 143
573 Strauss, W.H. and Klieser, E., Psychotropic effects of ritanserin, a selective $2 antagonist: an open study, 101 Streck, P., see G(inther, W., 143 Svennerholm, L., see Blennow, K., 79 Svennerholm, L., see Wallin, A., 165 Sykes, E.A., see Hughes, M.J., 45 Takagi, H., see Harima, A., 529 Taubert, S., see Becker, T., 83 Tolvanen, E., see Lublin, H., 541 Toussaint, C., see Ansseau, M., 113 Tr/iskman-Bendz, L., see Simonsson, P., 503 Troisfontaines, B., see Ansseau, M., 113 Van Van Van Van
den Hoofdakker, R.H., see Kemperman, C.J.F., 67 Ree, J.M., see Popik, P., 555 Ree, J.M., see Ramsey, N.F., 55 Ree, J.M., see Sekiguchi, R., 123
Vieira, A., see Kasper, S., 107 Villardita, C., see Senin, U., 511 Voll, G., see Kasper, S., 107 Volterra, G., Cutrufo, C. and Lecci, A., m-Trifluoromethylphenylpiperazine and m-chlorophenylpiperazine-induced hypothermia in mice is reversed by tricyclic antidepressants and other drugs, 519 Von Frenckell, R., see Ansseau, M., 113 Wallin, A., Carlsson, A., Ekman, R., Gottfries, C.-G., Karlsson, I., Svennerholm, L. and Widerl6v, E., Hypothalamic monoamines and neuropeptides in dementia, 165 Wallin, A., see Blennow, K., 79 Watanabe, S., see Inagawa, K., 549 Widerl6v, E., see Wallin, A., 165 Wilhelm, K.-R., see Sauer, H., 71 Wolterink, G., see Sekiguchi, R., 123